Levothyroxine dose following thyroidectomy is affected by more than just body weight

Kara Meinke Baehr, Elizabeth Lyden, Kelly Treude, Judi Erickson, Whitney S Goldner

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives/Hypothesis: To determine the factors that affect levothyroxine (LT4) requirements following thyroidectomy. Study Design: Retrospective study. Methods: This study evaluated 246 participants who had undergone total thyroidectomy and were on a stable dose of LT4. Actual weight-based (AWB) and ideal body weight-based (IBWB) LT4 dose requirements were analyzed, and other confounders including adherence, concurrent medications, comorbidities, female menopausal status, and hormone replacement therapy were examined. Results: A total of 205 women and 41 men were evaluated, with 48 (20%) benign and 198 (80%) malignant pathology findings. The mean AWB LT4 doses for men and premenopausal women were similar among members of the benign groups and similar among members of the malignant groups. There was a trend for lower dose LT4 in postmenopausal women off hormonal therapy (PM/NH) and on hormonal therapy (PM/H) in the benign group (1.4 and 1.6 μg/kg vs. 1.8 μg/kg in the men and premenopausal women) and a trend for lower dose LT4 in the PM/H women in the malignant group (1.9 μg/kgvs. 2.1 and 2.2 μg/kg in the men and premenopausal women), but they were not significant. However, PM/NH women required significantly less LT4 (1.7 μg/kg) than both the men (2.2 μg/kg) and premenopausal women (2.1 μg/kg) in the malignant group (P=.0006). The IBWB LT4 dosage was not statistically different between groups. Conclusions: LT4 dosage following thyroidectomy, calculated using actual body weight, can range from 1.4 to 2.2 μg/kg and is dependent on diagnosis (benign vs. malignant), goal TSH, sex, and menopausal status.

Original languageEnglish (US)
Pages (from-to)834-838
Number of pages5
JournalLaryngoscope
Volume122
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Thyroidectomy
Thyroxine
Body Weight
Ideal Body Weight
Weights and Measures
Medication Adherence
Hormone Replacement Therapy
Comorbidity
Retrospective Studies
Pathology
Therapeutics

Keywords

  • Thyroidectomy
  • levothyroxine
  • thyroid cancer
  • thyroid hormone replacement
  • thyroid nodules

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Levothyroxine dose following thyroidectomy is affected by more than just body weight. / Baehr, Kara Meinke; Lyden, Elizabeth; Treude, Kelly; Erickson, Judi; Goldner, Whitney S.

In: Laryngoscope, Vol. 122, No. 4, 01.04.2012, p. 834-838.

Research output: Contribution to journalArticle

Baehr, Kara Meinke ; Lyden, Elizabeth ; Treude, Kelly ; Erickson, Judi ; Goldner, Whitney S. / Levothyroxine dose following thyroidectomy is affected by more than just body weight. In: Laryngoscope. 2012 ; Vol. 122, No. 4. pp. 834-838.
@article{64c4d9273300412bbd53f7f8d9714ad8,
title = "Levothyroxine dose following thyroidectomy is affected by more than just body weight",
abstract = "Objectives/Hypothesis: To determine the factors that affect levothyroxine (LT4) requirements following thyroidectomy. Study Design: Retrospective study. Methods: This study evaluated 246 participants who had undergone total thyroidectomy and were on a stable dose of LT4. Actual weight-based (AWB) and ideal body weight-based (IBWB) LT4 dose requirements were analyzed, and other confounders including adherence, concurrent medications, comorbidities, female menopausal status, and hormone replacement therapy were examined. Results: A total of 205 women and 41 men were evaluated, with 48 (20{\%}) benign and 198 (80{\%}) malignant pathology findings. The mean AWB LT4 doses for men and premenopausal women were similar among members of the benign groups and similar among members of the malignant groups. There was a trend for lower dose LT4 in postmenopausal women off hormonal therapy (PM/NH) and on hormonal therapy (PM/H) in the benign group (1.4 and 1.6 μg/kg vs. 1.8 μg/kg in the men and premenopausal women) and a trend for lower dose LT4 in the PM/H women in the malignant group (1.9 μg/kgvs. 2.1 and 2.2 μg/kg in the men and premenopausal women), but they were not significant. However, PM/NH women required significantly less LT4 (1.7 μg/kg) than both the men (2.2 μg/kg) and premenopausal women (2.1 μg/kg) in the malignant group (P=.0006). The IBWB LT4 dosage was not statistically different between groups. Conclusions: LT4 dosage following thyroidectomy, calculated using actual body weight, can range from 1.4 to 2.2 μg/kg and is dependent on diagnosis (benign vs. malignant), goal TSH, sex, and menopausal status.",
keywords = "Thyroidectomy, levothyroxine, thyroid cancer, thyroid hormone replacement, thyroid nodules",
author = "Baehr, {Kara Meinke} and Elizabeth Lyden and Kelly Treude and Judi Erickson and Goldner, {Whitney S}",
year = "2012",
month = "4",
day = "1",
doi = "10.1002/lary.23186",
language = "English (US)",
volume = "122",
pages = "834--838",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Levothyroxine dose following thyroidectomy is affected by more than just body weight

AU - Baehr, Kara Meinke

AU - Lyden, Elizabeth

AU - Treude, Kelly

AU - Erickson, Judi

AU - Goldner, Whitney S

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Objectives/Hypothesis: To determine the factors that affect levothyroxine (LT4) requirements following thyroidectomy. Study Design: Retrospective study. Methods: This study evaluated 246 participants who had undergone total thyroidectomy and were on a stable dose of LT4. Actual weight-based (AWB) and ideal body weight-based (IBWB) LT4 dose requirements were analyzed, and other confounders including adherence, concurrent medications, comorbidities, female menopausal status, and hormone replacement therapy were examined. Results: A total of 205 women and 41 men were evaluated, with 48 (20%) benign and 198 (80%) malignant pathology findings. The mean AWB LT4 doses for men and premenopausal women were similar among members of the benign groups and similar among members of the malignant groups. There was a trend for lower dose LT4 in postmenopausal women off hormonal therapy (PM/NH) and on hormonal therapy (PM/H) in the benign group (1.4 and 1.6 μg/kg vs. 1.8 μg/kg in the men and premenopausal women) and a trend for lower dose LT4 in the PM/H women in the malignant group (1.9 μg/kgvs. 2.1 and 2.2 μg/kg in the men and premenopausal women), but they were not significant. However, PM/NH women required significantly less LT4 (1.7 μg/kg) than both the men (2.2 μg/kg) and premenopausal women (2.1 μg/kg) in the malignant group (P=.0006). The IBWB LT4 dosage was not statistically different between groups. Conclusions: LT4 dosage following thyroidectomy, calculated using actual body weight, can range from 1.4 to 2.2 μg/kg and is dependent on diagnosis (benign vs. malignant), goal TSH, sex, and menopausal status.

AB - Objectives/Hypothesis: To determine the factors that affect levothyroxine (LT4) requirements following thyroidectomy. Study Design: Retrospective study. Methods: This study evaluated 246 participants who had undergone total thyroidectomy and were on a stable dose of LT4. Actual weight-based (AWB) and ideal body weight-based (IBWB) LT4 dose requirements were analyzed, and other confounders including adherence, concurrent medications, comorbidities, female menopausal status, and hormone replacement therapy were examined. Results: A total of 205 women and 41 men were evaluated, with 48 (20%) benign and 198 (80%) malignant pathology findings. The mean AWB LT4 doses for men and premenopausal women were similar among members of the benign groups and similar among members of the malignant groups. There was a trend for lower dose LT4 in postmenopausal women off hormonal therapy (PM/NH) and on hormonal therapy (PM/H) in the benign group (1.4 and 1.6 μg/kg vs. 1.8 μg/kg in the men and premenopausal women) and a trend for lower dose LT4 in the PM/H women in the malignant group (1.9 μg/kgvs. 2.1 and 2.2 μg/kg in the men and premenopausal women), but they were not significant. However, PM/NH women required significantly less LT4 (1.7 μg/kg) than both the men (2.2 μg/kg) and premenopausal women (2.1 μg/kg) in the malignant group (P=.0006). The IBWB LT4 dosage was not statistically different between groups. Conclusions: LT4 dosage following thyroidectomy, calculated using actual body weight, can range from 1.4 to 2.2 μg/kg and is dependent on diagnosis (benign vs. malignant), goal TSH, sex, and menopausal status.

KW - Thyroidectomy

KW - levothyroxine

KW - thyroid cancer

KW - thyroid hormone replacement

KW - thyroid nodules

UR - http://www.scopus.com/inward/record.url?scp=84858749815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858749815&partnerID=8YFLogxK

U2 - 10.1002/lary.23186

DO - 10.1002/lary.23186

M3 - Article

C2 - 22374624

AN - SCOPUS:84858749815

VL - 122

SP - 834

EP - 838

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 4

ER -